Vector Genome Integrity

Vector genome integrity describes whether the encapsidated genetic payload in an AAV product is full-length, structurally correct, and free from major truncations, rearrangements, or unintended genome species.

This attribute is distinct from genome titer and empty/full capsid ratio. Genome titer estimates the number of vector genomes present, and empty/full analysis estimates whether capsids contain DNA. Genome integrity asks whether the packaged DNA is the intended genome. A product can have an acceptable genome titer and a favorable full-capsid profile while still containing truncated or rearranged genomes that may reduce potency or contribute to product-related impurity risk.

In CMC practice, vector genome integrity supports identity, purity, potency, comparability, and process consistency. It is especially important for AAV products because packaged genome integrity can be affected by vector design, plasmid quality, production conditions, capsid stability, purification stress, and analytical sample preparation.

Genome integrity is typically characterized or monitored using orthogonal methods such as capillary gel electrophoresis (CGE), next-generation sequencing (NGS), restriction enzyme mapping, and quantitative PCR/ddPCR mapping. Alkaline agarose gel electrophoresis (AAGE) can be useful for qualitative characterization or orthogonal confirmation, but a validated, quantitative method is generally more appropriate when genome integrity is used for formal release testing or product-specific specifications.

• Quantitative Extraction: A key analytical challenge is disrupting the AAV capsid and recovering encapsidated DNA efficiently without introducing sample-preparation artifacts. Once capsids are disrupted, exposed single-stranded DNA may be vulnerable to nuclease-mediated degradation or loss during extraction. Method conditions should minimize degradation, incomplete recovery, and artificial shifts in fragment-size distribution.
• Resolution and Sensitivity: The analytical method must have sufficient resolution to distinguish the full-length genome from slightly truncated forms, which may only differ in size by a small percentage.
• Lack of a Truncated Genome Standard: Because isolating a stable, native truncated-genome reference standard is operationally difficult, assay validation often relies on alternative strategies such as engineered shortened vector controls, intentionally degraded or stressed samples, or model mixtures that demonstrate resolution, sensitivity, specificity, and quantitative performance for truncated or unintended genome species.

• Early Development: Assays for genome integrity are typically used for characterization only. The goal is to gain an initial understanding of the product and the consistency of the manufacturing process.
• Mid-Development: The method is optimized and qualified. It is used to assess the impact of any process changes on the quality of the packaged DNA. An understanding of the acceptable level of truncated forms begins to be established.
• Late-Stage / BLA Submission: A validated, high-resolution method is expected. Regulators now frequently expect a formal specification for the percentage of full-length, intact vector genomes. This is a key component of the overall purity and potency control strategy.
• Investing in a high-resolution, validated integrity method early is a critical de-risking activity. Failure to generate a comprehensive data package can lead to significant regulatory questions and potential delays during BLA/MAA review.

• Patient Risk: A vector with a truncated or rearranged genome may fail to produce the intended therapeutic protein, contributing to reduced potency or underdosing risk. In some cases, unintended genome species could theoretically express non-functional or immunogenic protein fragments.

  Genome integrity assessment should also consider encapsidated non-vector DNA, including residual host-cell DNA or plasmid-backbone sequences such as antibiotic-resistance or helper/plasmid-derived elements. These species are relevant to product-related and process-related impurity risk and may raise safety concerns related to immunogenicity, oncogenic sequence content, or genotoxicity/integration-related risk depending on sequence identity, quantity, and biological context.

• Manufacturing Risk: A high percentage of truncated or modified genomes is a direct indicator of a poorly controlled manufacturing process. This could stem from issues with the quality of the starting plasmid DNA, shearing forces during purification, or instability of the vector.

• This attribute provides the crucial qualitative context for the quantitative Genome Titer result.
• It is a more detailed investigation of the particles deemed "full" in the Empty/Full Ratio analysis. A particle can be full of DNA, but if the DNA is not intact, the particle is not functional.
• A loss of genome integrity will lead directly to a loss of Potency, as the correct therapeutic protein cannot be expressed.

Vector genome integrity has become an increasingly important part of AAV product characterization and control strategy. Genome titer by qPCR or dPCR supports dose expression, but it does not by itself confirm that the packaged genome is full-length or structurally correct.

For AAV products, sponsors commonly use orthogonal genome-integrity methods to evaluate full-length genome content, truncated genomes, rearranged genomes, and other unintended genome species. The appropriate control strategy depends on vector design, impurity profile, analytical method capability, clinical stage, and relationship to potency or comparability.

As programs mature, genome-integrity data are expected to support process understanding, comparability after manufacturing changes, and justification of product-specific specifications or acceptance criteria where appropriate.

For AAV products, genome-integrity characterization increasingly overlaps with impurity characterization because the key question is not only whether the intended genome is full-length, but also whether unintended encapsidated DNA species are present at levels relevant to safety, potency, or process consistency.

ICH Q6B: For biotechnology/biological products, product-related impurities and degradation products should be characterized and controlled where relevant to quality, safety, or efficacy. For AAV products, truncated or rearranged genomes can be treated as product-related impurity species when they arise from the intended product or manufacturing process.

FDA Human Gene Therapy CMC Guidance: FDA expects gene therapy IND submissions to describe product manufacturing, testing, and characterization. For AAV products, genome integrity is part of the broader characterization and control strategy needed to understand the final vector product.

Comparability and Lifecycle Control: Genome-integrity methods can be important when evaluating manufacturing changes, scale changes, process optimization, or analytical method changes because shifts in full-length or unintended genome species may affect potency, purity, or product consistency.